Best Oncology Companies in Israel
The 150 best Oncology companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Vayyar.
Ranked by disclosed equity funding and recent momentum, the Israel Oncology companies in this directory represent one of the more concentrated bets in global biotech right now. One hundred and fifty companies. $1.4B in total disclosed funding. One unicorn. And Israel's position at the forefront of oncology innovation isn't hype, it's a capital story backed by names like Pontifax, Arkin Holdings, and the Israel Biotech Fund showing up repeatedly across the cap table.
The numbers scale fast from here. The global oncology market sits at roughly $250.9B in 2025 and is forecast to reach $668.3B by 2034, compounding at 11.5% annually, driven by rising cancer incidence and the continued expansion of precision medicine. Alpha Tau Medical leads this directory at $55M in disclosed funding, with OncoHost close behind at $43M. So when you're scanning this list, don't mistake modest raise sizes for modest ambition. Cost-containment policies are tightening payer leverage globally, which means the companies with the clearest biomarker data and clinical differentiation are the ones worth watching. I'd start there.
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Value to More Than Double, Reaching USD 748.17 Billion
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Israel
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Vayyar 🦄 Developer of 4D imaging sensors for cancer detection and other devices | $296M | 48 mo ago | 330 | Raviv Melamed Co-Founder & CEO | Series E | Top 5M | — | — |
| 2 | Gamida Cell Developer of cell therapies to treat cancer and other serious diseases | $139M | 107 mo ago | 146 | Joseph Wiley CEO and Chairman | Public | Top 10M | 211 patents Allogeneic NK and gamma‑delta T cell immunotherapy manufacturing from cord‑derived cells | 1 partnership |
| 3 | NeoTX Combinational tumor-targeting protein drugs for cancer | $101M | 76 mo ago | 33 | Asher Nathan CEO | Series C | — | — | — |
| 4 | Nucleix Developer non-invasive molecular cancer diagnostic tests | $88M | 53 mo ago | 62 | — | Series C | Top 50M | 163 patents Epigenetic DNA methylation profiling for cancer and prenatal liquid biopsy diagnostics. | — |
| 5 | NovellusDx Developer of technology for precision cancer diagnosis and therapies | $86M | 68 mo ago | 49 | — | Series C | — | 46 patents Patient-specific cancer mutation identification, functional validation, and drug response profiling | — |
| 6 | BioSight Developer of therapeutics for oncology & hematological disorders | $59M | 66 mo ago | 10 | — | Acquired | — | 90 patents Prodrug conjugates of cytarabine with amino acids for targeted cancer chemotherapy | — |
| 7 | KAHR Developer of immune therapeutics to treat cancer | $58M | 43 mo ago | 32 | Yaron Pereg CEO | Series D | — | — | — |
| 8 | Alpha Tau Medical Developer of radiotherapy technique for the treatment of solid cancer tumors 62Patents top 14%Innovation top 24%Funding top 26%Moat top 26% All 10 signals ▾Patentstop 14% Innovationtop 24% Fundingtop 26% Moattop 26% Techtop 43% Growthtop 48% Marketbottom 49% Talentbottom 49% Globalbottom 45% Newsbottom 21% Patents: 332 patents matched (strict assignee match) · 279 filings since 2022 vs 53 in 2017-21 Innovation: 332 patents (top 8% of patent-holders) · 279 filings since 2022 vs 53 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $55M | 13 mo ago | 89 | Uzi Sofer CEO | Public | Top 10M | 332 patents Alpha-emitting radiopharmaceuticals and delivery devices for targeted cancer therapy | 1 partnership |
| 9 | BioProtect Developer of radiation protection technology | $46M | 32 mo ago | 1 | Shaul Shohat Co-Founder & CTO | Acquired | Top 10M | 57 patents Provides inflatable bladder and dilator devices for tissue protection during minimally invasive procedures. | 1 award |
| 10 | ONCOHOST AI-based oncology therapy plan solution for professionals 64Patents top 27%Moat top 28%Talent top 28%Innovation top 29% All 10 signals ▾Patentstop 27% Moattop 28% Talenttop 28% Innovationtop 29% AItop 30% Fundingtop 31% Techbottom 42% Marketbottom 41% Globalbottom 35% Newsbottom 18% Patents: 55 patents matched (strict assignee match) · 38 filings since 2022 vs 17 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 55 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $43M | 13 mo ago | 48 | Yuval Shaked Co-Founder | Series C | Top 50M | 55 patents AI-driven predictive analytics for personalized cancer treatment response and biomarker identification | 2 job openings |
| 11 | Illumigyn Developer of colonoscope for cervical cancer detection interventional procedures | $38M | 55 mo ago | 25 | Lior Greenstein Executive Board Member Founder Technology Advisor | Series B | — | 38 patents Gynecological optical speculum devices for in‑vivo imaging and targeted tissue removal | — |
| 12 | Metabomed Developer of targeted therapies to treat cancer | $36M | 78 mo ago | 7 | — | Deadpooled | — | 53 patents ACSS2 enzyme inhibitors for metabolic and oncology drug development | — |
| 13 | Compugen Immuno-oncology company with propreitary in-silico drug discovery platform | $35M | 55 mo ago | 20 | Amir Natan Co-Founder | Public | Top 10M | 624 patents Immune checkpoint antibody therapeutics targeting PVRIG, TIGIT, IL‑18BP, PD‑1. | — |
| 14 | Biond Biologics Developer of immunotherapies for oncology and autoimmune diseases | $32M | 54 mo ago | 34 | — | Series C | Top 50M | 141 patents Immuno‑oncology biologics: intracellular delivery systems and checkpoint‑blocking antibodies (ILT2/3, CD28). | — |
| 15 | Lutris Pharma Provider of anti-cancer therapy 29Patents top 32%Moat top 32%Funding top 33%Talent top 33% All 9 signals ▾Patentstop 32% Moattop 32% Fundingtop 33% Talenttop 33% Innovationtop 38% Globalbottom 40% Techbottom 31% Newsbottom 18% Marketbottom 17% Patents: 75 patents matched (strict assignee match) · 41 filings since 2022 vs 34 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 75 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $30M | 16 mo ago | 4 | Antoni Ribas Founder & Chairman | Series B | Top 50M | 75 patents Topical BRAF kinase inhibitors for EGFR‑related skin toxicities and isoquinoline wound‑healing agents | — |
| 16 | P-Cure Imaging-based proton radiation therapy for cancer treatment | $30M | 83 mo ago | 31 | Michael Marash Founder & CEO | Series B | Top 50M | 70 patents Integration of proton therapy systems and patient positioning/support devices for radiotherapy | — |
| 17 | MobileODT Provider of AI-based diagnostic tools for the screening of cervical cancer | $26M | 64 mo ago | 18 | — | Acquired | Top 10M | 26 patents Automated cervical cancer imaging and AI-based detection using enhanced optical illumination. | — |
| 18 | Vessi Medical Provider of method for treating bladder cancer | $18M | 28 mo ago | 3 | — | Series A | — | — | — |
| 19 | Starget Pharma Developer of targeted radiopharmaceuticals technologies to treat solid tumors 32Growth top 35%Talent top 38%Partners top 45%Funding top 48% All 8 signals ▾Growthtop 35% Talenttop 38% Partnerstop 45% Fundingtop 48% Moattop 48% Techbottom 36% Globalbottom 36% Marketbottom 28% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 32/100 | $15M | 5 mo ago | — | Ronen Kalmanson Co-Founder | Series A | Top 50M | — | 1 award |
| 20 | Curesponse Provider of a tissue culture system to analyze cancer growth and drug response | $14M | 55 mo ago | 16 | Guy Neev Co-Founder & CEO | Series B | Top 50M | — | — |
| 21 | IceCure Medical Ultrasound-guided cryoblation to treat breast fibroadenomas | $14M | 70 mo ago | 72 | Eyal Shamir CEO | Public | Top 10M | 62 patents Medical cryotherapy devices and cryogenic delivery systems for tissue ablation | — |
| 22 | RedHill Biopharma Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | $14M | 28 mo ago | 183 | — | Public | Top 5M | 261 patents Antiviral and anticancer drug compositions, especially kinase and protease inhibitors, and combination therapies. | — |
| 23 | Novocure Developer of therapeutics to treat solid tumours | $10M | 67 mo ago | 1,320 | Yoram Palti Founder | Public | Top 5M | 99 patents Electric field-based cancer therapy devices and methods, including transducer arrays and combinatorial treatments. | 1 award |
| 24 | Check-Cap Developer of imaging capsules for colorectal cancer screening | $10M | 70 mo ago | 81 | — | Public | Top 50M | 146 patents Ingestible radiation imaging capsules with AI for GI disease detection and drug delivery | — |
| 25 | Vidac Pharma HK2-VDAC protein interaction disruptors for oncologic and oncodermatologic diseases. 21Product top 36%Growth top 45%Patents top 47%Moat top 47% All 9 signals ▾Producttop 36% Growthtop 45% Patentstop 47% Moattop 47% Innovationbottom 48% Fundingbottom 45% Techbottom 36% Globalbottom 35% Marketbottom 23% Product: 8 distinct product lines · Company stage: Series A Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $10M | 19 mo ago | 9 | — | Series A | Top 10M | 44 patents Patents concentrated in health & consumer products | — |
| 26 | Todos Medical Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders | $7M | 56 mo ago | 7 | — | Public | — | 42 patents Blood-based infrared spectroscopy for Alzheimer’s and cancer biomarker detection | — |
| 27 | Senseera Provider of liquid biopsy blood tests for cancer diagnosis 35Talent top 28%Funding top 46%Market bottom 37%Global bottom 36% All 4 signals ▾Talenttop 28% Fundingtop 46% Marketbottom 37% Globalbottom 36% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $7.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $7M | 17 mo ago | — | Nir Friedman Co-Founder | Seed | — | — | — |
| 28 | UroGen Pharma Developer of therapeutics to treat urothelial and specialty cancers | $7M | 34 mo ago | 150 | Ron Bentsur CEO | Public | Top 10M | 80 patents Intravesical drug delivery systems and immunomodulatory therapies for urinary tract cancers | — |
| 29 | JaxBio Developer of an AI-based chip for genetic and epigenetic profiling | $6M | 23 mo ago | — | Dror Feldheim Co-Founder | Seed | — | — | — |
| 30 | Trobix Bio Developer of microbiome-based therapeutics that address various therapeutic areas | $6M | 38 mo ago | 9 | — | Series A | — | — | — |
| 31 | Quiet Therapeutics Lipid nanoparticles as a mode of delivery to target cancer cells | $6M | 161 mo ago | 4 | Dan Peer Co-Founder | Series A | — | 8 patents Lipidated glycosaminoglycan carriers for nucleic acid delivery | — |
| 32 | MyBiotics Developer of microbiome-based therapeutics to treat various diseases | $5M | 48 mo ago | 27 | David Daboush Co-Founder & CEO | Seed | — | — | — |
| 33 | Efranat Cancer immunotherapies based on glycoprotein mimics | $4M | 139 mo ago | 13 | Uri Yogev CEO | Series A | — | 19 patents Immunomodulatory biologics targeting macrophage activation for cancer and papilloma therapy | — |
| 34 | Biop Medical Point-of-care diagnostic solutions for cervical cancer. | $4M | 93 mo ago | 9 | Dalit Milo Co-Founder | Series A | — | — | — |
| 35 | Metallo Therapy Tumor-targeted contrast agents based on surface-modified gold nanoparticles | $4M | 181 mo ago | — | Amal Ayoub Founder & CEO | Deadpooled | — | 8 patents Surface-modified heavy‑metal nanoparticle drug delivery systems for therapeutic applications | — |
| 36 | CAPS Medical Developer of cold atmospheric plasma technology for treating tumour | $4M | 70 mo ago | 13 | Ilan Uchitel CEO | Series A | Top 50M | 50 patents Patents concentrated in health & consumer products | — |
| 37 | Novotyr IGF1R inhibitors for the treatment of cancer | $4M | 216 mo ago | — | Hadas Reuveni CEO | Deadpooled | — | — | — |
| 38 | HIL Medical Developer of proton-beam radiotherapy device to treat solid tumors | $3M | 37 mo ago | — | Arie Zigler Co-Founder | Series C | Top 10M | 42 patents Advanced ion/charged-particle therapy systems for precise cancer radiation delivery | — |
| 39 | Eventus Diagnostics Immune system-based blood tests for the detection of breast cancer | $3M | 146 mo ago | — | Marvin Rosenberg Co-Founder & President | Deadpooled | — | 5 patents Immunoassay-based detection of cancer biomarkers | — |
| 40 | Helix Medical Systems Ultrasound systems for breast imaging | $3M | 221 mo ago | — | Arie Amara Co-Founder & ex-CEO | Deadpooled | — | — | — |
| 41 | Predictive Therapeutics Developing tumor-cell coating molecules as therapy for cancer | $2M | 128 mo ago | — | Asher Nathan Co-Founder & CEO | Series A | — | — | — |
| 42 | Omrix Biopharmaceuticals Developer of biopharmaceutical products derived from human plasma | $2M | 256 mo ago | — | — | Acquired | — | 652 patents Oxidized cellulose-based hemostatic and anti‑adhesion biomaterials for surgical wound care | — |
| 43 | Tiltan Pharma Develops therapeutics for treatment of metastatic pancreatic cancer using combinatorial drug therapy… | $2M | 148 mo ago | — | Yigal Stav CEO & Co-Founder | Deadpooled | — | 29 patents Oncologic combination drug regimens integrating H2 blockers, anti-inflammatories, and cytotoxics | — |
| 44 | Immunovative Therapies Developing personalized vaccines and activated T cells for the treatment of cancer and infectious diseases. | $2M | 221 mo ago | 18 | — | Series A | — | 287 patents Cell-based immunotherapies modulating Th1/Treg cytokines for infectious disease treatment | — |
| 45 | Limaca Medical Developing endoscopic ultrasound fine needle biopsy system | $1M | 67 mo ago | 5 | Assaf Klein CEO | Seed | — | 25 patents Percutaneous biopsy instruments for tissue penetration, separation, and sampling | 2 job openings · 1 partnership |
| 46 | Infiniplex Developer of liquid-biopsy based screening test for cancer | $1M | 48 mo ago | 8 | Ofer Peleg Co-Founder & CSO | Seed | — | 9 patents Multiplex nucleic acid diagnostic kits and selective PCR primers for rare target detection | — |
| 47 | Cell Source Cell therapy treatments for transplantation, cancer treatment and reversal of vital organ disease 7Funding top 48%Global bottom 38%Market bottom 20% All 3 signals ▾Fundingtop 48% Globalbottom 38% Marketbottom 20% Funding: Raised $398k across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Global: Serving 2 countries incl. United States, Israel rank vs industry peers · Fliar Intelligence Index 7/100 | $398K | 5 mo ago | 1 | — | Public | — | — | — |
| 48 | Immunyx Developer of neutrophil therapies for multiple diseases | $269K | 48 mo ago | 7 | Zvi Fridlender Co-Founder | Funding Raised | — | — | — |
| 49 | Savicell Metabolomics-based blood tests for early detection of cancer. | $224K | 34 mo ago | 7 | — | Seed | — | — | — |
| 50 | Magentiq Eye Computer vision technology in endoscopic procedures | $100K | 10 mo ago | 14 | — | Series A | Top 50M | 17 patents AI-driven computer‑aided detection and analysis of colonoscopic images for polyp identification | — |
Top 12 Oncology companies in Israel
#1
Series A · Ramat Hasharon, Tel Aviv District · founded 2019$15.1Mraised▾
Developer of targeted radiopharmaceuticals technologies to treat solid tumors. The company's research is in the development of molecules that serve as a vector for the targeted transfer of radioactive isotopes to cancerous tumors for diagnosis and targeted treatment of cancer.
- Jan 2026Series A$18M
- Oct 2024Series A$5.1M
- Dec 2021Series A$10M
#2
Public · Tel Aviv, Tel Aviv · founded 2015 · 89 employees$55Mraised▾
Developer of radiotherapy technique for the treatment of solid cancer tumors. The technology, known as Alpha DaRT treats solid tumors with interstitial radioactive seeds which release short-lived alpha-emitting atoms into the tumor continuously. This treatment does not have any effect on the surrounding healthy tissue.
- Apr 2025Post IPO$36.9M
- Jun 2020Series B$26M
- Sep 2018Series B$29M
- Jul 2017Series A—
#3
Series C · Binyamina Giv at Ada, Haifa District · founded 2017 · 48 employees$43Mraised▾
AI-based oncology therapy plan solution for patients and professionals. The company has developed a proprietary proteomic analysis that can analyze the proteomic changes in the blood sample induced by the patient in response to cancer therapy. The company also provide treatment strategy to improve the effectiveness of therapy. It also provides consultancy services to patients, oncologists, nurses, and pharma companies among others. The company has developed PROphet which is a bioinformatics tool used to identify proteomic patterns related to therapy.
- May 2025Grant (prize money)$2.8M
- May 2022Series C$35M
- Jan 2021Series B$8M
- Jan 2020Grant (prize money)—
#4
Series B · Tel Aviv, Tel Aviv · founded 2016 · 4 employees$30Mraised▾
Lutris Pharma is developing anticancer therapy based on EGFR (Epidermal Growth Factor Receptor) Inhibitors. It helps in reducing dose-limiting side effects mainly dermal toxicity. It develops its proprietary small molecule B-Raf-based inhibitor LUT014, reducing acneiform lesions. It is in phase 1 clinical trial.
- Jan 2025Series B$30M
#5
Public · Tel Aviv, Tel Aviv · founded 2011 · 1 employees$397.5Kraised▾
Cell Source is a biotechnology company developing cell therapy treatments based on the management of immune tolerance. Its flagship technology is the Veto Cell platform. Veto cells are white blood cells taken from either the patient or a healthy third-party donor. They are then processed using a mix of off-the-shelf cytokines that change their characteristics and activate their inherent “attacker blocking” capability. The company also has Megadose, a treatment involving a large number of stem cells to facilitate bone marrow transplants in cases with partially-matched donors. It is working on Megadose-drug combination platforms. It currently has 2 Megadose + drug combinations (PoC and pre-clinical stages) and 2 pre-clinical Veto cell programs for anti-rejection and anti-lymphoma.
- Jan 2026Post IPO$1.5M
- Oct 2023Post IPO$3.9M
- Oct 2019Post IPO$8.9M
- Nov 2015Seed$252.5K
#6
Seed · Jerusalem, Jerusalem District · founded 2020$7.1Mraised▾
Provider of liquid biopsy blood tests for cancer diagnosis. The cfChIP-seq technology can detect cell-free chromatin tissue which can be used to identify patient-specific gene expression for the detection of diseases and treatment response. The company uses molecular biology, next-generation sequencing, and computational analysis to extract epigenetic information.
- Jan 2025Seed$7.1M
#7
Series A · Jerusalem, Jerusalem District · founded 2011 · 9 employees$9.6Mraised▾
Vidac Pharma is focussed on developing medicines for a range of oncologic and oncodermatologic diseases. Its technology is based on modifying the HK2 (hexokinase enzyme)-VDAC (voltage-dependent anion channel) system which overexpresses in many cancer types. It is developing small molecule drugs which disrupt the protein interactions and can modulate this target for the selective apoptosis of cancer cells. Its lead product VDA-1102, a formulated topical ointment is being developed for actinic keratosis (phase 1 completed), Cutaneous Squamous Cell Carcinoma (phase 1) and Cutaneous Skin Lymphoma & solid tumors (pre-clinical). Besides, it is also developing VDA-1214, a systemic drug for treatment of solid tumors (pre-clinical).
- Nov 2024Series A$644.9K
- Jun 2016Series A$9M
#8
Vayyar 🦄Series E · Yehud, Center District · founded 2011 · 330 employees$296Mraised▾
Developer of 4D imaging sensors for cancer detection and other devices. It offers a hand-held screening device that generates high-resolution 3D images that detect breast cancer by using radio frequency technology. Also, it develops touchless fall detection for seniors. It provides various products for multiple industries such as retail, public safety, robotics, and smart buildings.
- Jun 2022Series E$108M
- Nov 2019Series D$109M
- Dec 2017Series C$45M
- Dec 2015Series B$22M
#9
Seed · Netanya, Central District · founded 2020$6Mraised▾
Developer of an AI-based chip for genetic and epigenetic profiling. It offers a set of biomarkers that assists with the identification of different kinds of cancer. It has features for diagnostic tests with a multi-cancer approach system. The chip can be used for detecting genetic and epigenetic profiles
- Jul 2024Grant (prize money)$2.7M
- Jan 2023Grant (prize money)$9.1M
- Jan 2023Grant (prize money)$1.9M
- 2022Seed$6M
#10
Acquired · Kokhav Ya ir Tzur Yigal, Center District · founded 2001 · 1 employees$46.1Mraised▾
BioProtect is developing radiation protection technology. The company has developed a BioProtect/ ProSpace Balloon System which acts as a spacer and pushes healthy tissue away from the high-dose radiation field for patients receiving radiotherapy for prostate cancer.
- Oct 2023Grant (prize money)$2.6M
- Sep 2020Series D$25M
- Jan 2020Series D$13M
- Apr 2017Series A$3.5M
#11
Public · Ramat Gan, Tel Aviv District · founded 2009 · 183 employees$13.5Mraised▾
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases. The company is focusing on the development of proprietary, orally-administered, small molecule drugs for the treatment of multiple diseases. The company’s product pipeline includes RHB-204, RHB-104, RHB-102, and RHB-106 for H. pylori infections, Crohn's disease, Gastroenteritis gastritis, solid tumor, pancreatic cancer, Migraine, and other diseases.
- Jan 2024Post IPO$10M
- Oct 2023Post IPO$4M
- Aug 2023Post IPO$2.7M
- Sep 2020Grant (prize money)$300K
#12
Series A · Misgav, Northern District · founded 2015 · 3 employees$18.2Mraised▾
Vessi Medical develops a method for treating Non-Muscle Invasive Bladder Cancer (NMIBC). The company uses surface cryotherapy, a method that utilizes extreme cold, to freeze and destroy abnormal tissue. The invasive solution for NMIBC provides a new, first-line, therapeutic alternative to surgery
- Feb 2024Series A$16.5M
- Aug 2020Seed$1.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Israel
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 263 Israel-affiliated papers.
- Tel Aviv University55
- Weizmann Institute of Science42
- Technion – Israel Institute of Technology42
- Hadassah Medical Center33
- Hebrew University of Jerusalem31
- Immune system2→40
- Tumor microenvironment5→42
- Cancer research6→30
- Immunotherapy1→24
- Cancer immunotherapy1→23
- Tumor microenvironment6→51
- Immune system3→37
- Cancer research2→30
- Immunotherapy2→30
- Melanoma2→8
- Tumor microenvironment1→11
- Immune system1→9
- Immunology1→4
- Cancer research1→4
Where oncology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.